Labiotech.eu

Will the daily routine of finger pricking to monitor blood sugar levels finally come to an end for the millions living with diabetes? The post Needle-free diabetes care: 6 devices that painlessly monitor blood sugar appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author a…

Let’s pick up the bagpipes as we take a look at 5 biotech companies in Scotland driving the country's flourishing life sciences scene. The post Five companies pushing biotech in Scotland appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohi…

This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epic Bio. The post How Epic Bio is leveraging CRISPR without cutting DNA appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibit…

Discover the emerging class of degrader–antibody conjugates – a modality that is drawing increasing interest from biotech companies. The post When ADCs meet targeted protein degraders: The emerging field of degrader-antibody conjugates appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from …

There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit the clinic. The post CAR-T cell therapies going in vivo appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. E…

We take a closer look at Gilead's pipeline strategy and dealmaking activity in 2026 as the company attempts to broaden its focus beyond HIV. The post Gilead’s pipeline strategy in 2026: A broadening focus beyond HIV appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author a…

Single-cell omics is reshaping drug discovery, but turning complex data into biological insight remains slow. AI may help close the annotation gap. The post AI in single-cell analysis: solving the interpretation gap appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author a…

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising preclinical results. The post Modified CRISPR tool targets Down syndrome mutation appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is stri…

Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics. In this episode, Patrick walks us through the company’s DIAGONAL platform, and its lead program DIAG723 The post Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material …

AACR 2026 saw thousands gathered in San Diego, California, where major progress in cancer research was revealed. The post AACR 2026: where is cancer therapeutics heading? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts …

Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers. The post PARP inhibitors: a proven class facing limits appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts …

Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the field. The post What new atopic dermatitis treatments are in the pipeline in 2026? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or ow…

With no approved drug therapies for HIE, some clinical progress has been made over the past decade, as one treatment nears regulatory clearance. The post Therapy for brain injuries in infants bags funding: is the first HIE drug on the way? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission f…

Our guest today is Thierry Laugel, Managing Partner of Kurma & Chairman of Argobio. Argobio has co-founded several companies from top European academic labs. The post Argobio: the venture model building Europe’s next biotech champions appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from t…

Discover eight allergy companies leading the way in 2026, developing allergy therapies that go beyond emergency management. The post Eight allergy companies to watch in 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerp…

Discover how VCs and universities can work together to overcome the various challenges that affect current relations. The post Mending university and venture capital relations: is it possible to see eye-to-eye? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or…

Effective new antibiotics are thin on the ground. Could bacteria-eating phage viruses be the answer to this problem? The post Can phage therapy answer the booming antibiotic resistance problem? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictl…

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines. The post Amgen pipeline’s next growth cycle: replacing its old blockbusters appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly proh…

Discover what were the top biotech deals that were signed in March 2026. From small molecules to antibodies, M&A activity was high. The post Top biotech deals in March 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpt…

Today, we're exploring the transformative potential of AI in biopharma with our guest, Parashar Dhapola, co-founder and CEO of Nygen Analytics. The post Multi-agent AI delivers reliable and scalable insights for single-cell omics appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this s…